Home / Biopharma / Stock Sparks Rallying on Rosy Data: IntelliPharmaCeutics International (NASDAQ:IPCI), Arena Pharmaceuticals (NASDAQ:ARNA)

Stock Sparks Rallying on Rosy Data: IntelliPharmaCeutics International (NASDAQ:IPCI), Arena Pharmaceuticals (NASDAQ:ARNA)

Following previous ticker characteristics, IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) also run on active notice, stock price shows upbeat performance surged 19.33% after traded at $2.84 in most recent trading session. the firm reported that it attained a tentative authorization from the U.S. Food and Drug Administration. Specifically, the tentative authorization was for the firm’s abbreviated new drug application (ANDA) for quetiapine fumarate extended-release tablets in varying doses.

The tentatively-agreed product is a generic equivalent for the corresponding strengths of the branded product Seroquel XR sold in the U.S. by AstraZeneca. For some quick background, Seroquel XR, and the drug active quetiapine fumarate, are indicated for use in the treatment of schizophrenia and bipolar disorder. According to the settlement among IntelliPharmaCeutics and AstraZeneca from July 2012, the firm is permitted to launch its generic version of Seroquel XR in certain varying doses on November 1, 2016.

IPCI price to current year EPS stands at -87.00%. Whereas the traders who further want to see about this, may be interested to see Price to next year’s EPS that would be 189.30%. Moving toward ratio analysis, it has current ratio of 0.30 and quick ratio was calculated as 0.30.

Taking notice on volatility measures, price volatility of stock was 10.00% for a week and 9.92% for a month. The price volatility’s Average True Range for 14 days was 0.22. On these bases, analysts would recommend this stock as an “Active Revolving Stocks.” The firm attains analyst recommendation of 1.30 out of 1-5 scale with week’s performance of 26.22%. IPCI’s institutional ownership was registered as 0.50%, while insider ownership was 56.50%.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) persists its position slightly strong in context of buying side, while shares price shows upbeat performance surged remains unchanged during latest trading session.

Narrow down focus to other ratios, the co has current ratio of 2.60 that indicates if ARNA lies in 1.3% to 3% then it is acceptable for both active and passive investors, but sometimes its varies industry to industry. Generally, it indicates good short-term financial strength. Street is more conscious on this after SunEdison, Inc. case. To make strengthen these views, the active industry firm has Quick Ratio of 2.40, which indicates firm has sufficient short-term assets to cover its immediate liabilities. In addition, the firm has debt to equity ratio of 4.91, sometimes its remain same with long term debt to equity ratio.


About Blake Escott

Blake Escott holds junior writer position in SWR. Before joining Streetwise Report, he was a freelance content Writer. He has high-level copywriting experience and particularly experienced in proofreading and editing. He covers news about different companies including all US market sectors. Interests: Commodities, Energy stocks, Sector-wise Stocks analysis, Utilities

Check Also

Stocks Faring Away From Broker’s Choice: Opko Health (NASDAQ:OPK), Shire plc (NASDAQ:SHPG)

Several matter pinch shares of Opko Health, Inc. (NASDAQ:OPK) [Trend Analysis], as shares plunging -2.56% …

Leave a Reply

Your email address will not be published. Required fields are marked *